About CSTONE PHARMA-B Company

Cornerstone Pharmaceuticals was created to meet the needs of cancer patients, focusing on the development and commercialization of innovative tumor immunotherapy and molecular targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team and has rich experience in pre-clinical research, clinical development and commercialization. Through a dual source of innovation composed of internal R&D and external cooperation, the company has built a strong anti-tumor drug pipeline with 14 drug candidates, including 4 exclusive cooperation and authorized products between Blueprint Medicine and Agios Pharmaceuticals, which together with the self-developed pipeline have significant potential and synergy effects for single and combination therapies. Of the drug candidates under development, 4 are in or near critical testing. Cornerstone Pharmaceuticals' business model is driven by clinical research and development, while rapidly establishing commercialization and production capacity. The company received support from well-known investors, and the amount of round A and B financing both broke records in the biomedical field at the time. The total amount of the two rounds of financing was 0.412 billion US dollars. With an experienced team, a promising R&D pipeline, a strong business model, and sustainable financial support, Cornerstone's vision is to become a world-renowned leading Chinese biopharmaceutical company by bringing innovative and differentiated oncology therapies to cancer patients around the world.